VRDN250117P22500
- 3.50
- 0.000.00%
Viridian Therapeutics Newsroom
Is Viridian Therapeutics, Inc. (NASDAQ:VRDN) Worth US$19.3 Based On Its Intrinsic Value?
Wells Fargo Downgrades Viridian Therapeutics(VRDN.US) to Hold Rating, Cuts Target Price to $27
This C3.ai Analyst Turns Bearish; Here Are Top 5 Downgrades For Thursday
Wells Fargo Downgrades Viridian Therapeutics to Equal-Weight, Announces $27 Price Target
Buy Rating Reaffirmed for Viridian Therapeutics: Promising Phase 3 Results for Veligrotug in TED Treatment
RBC Capital Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Raises Target Price to $47
Breaking Down Viridian Therapeutics: 10 Analysts Share Their Views
Viridian Therapeutics Sees Stock Soar After Phase III TED Success
TD Cowen Maintains Viridian Therapeutics(VRDN.US) With Buy Rating
TD Cowen Remains a Buy on Viridian Therapeutics (VRDN)
Oppenheimer Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $28
A Quick Look at Today's Ratings for Viridian Therapeutics(VRDN.US), With a Forecast Between $34 to $61
Viridian Therapeutics (VRDN) Gets a Buy From Oppenheimer
Express News | Viridian Therapeutics Inc : RBC Raises Target Price to $47 From $44
9 Health Care Stocks With Whale Alerts In Today's Session
Tesla, Micron, Broadcom, MARA Holdings And Other Big Stocks Moving Higher On Monday
HC Wainwright & Co. Reiterates Buy on Viridian Therapeutics, Maintains $34 Price Target
Viridian Therapeutics' Veligrotug: Promising Phase 3 Results and Strong Buy Rating
Viridian Therapeutics Meets Endpoints in Late-Stage Veligrotug Trial for Thyroid Eye Disease
Viridian Therapeutics Achieves Milestone in Phase 3 Trial